In an NSCLC model (NSCLC HCC827, H1975, A549, H292, and H1299 gefitinib-resistant cell lines), integrin β3 constitutes a target of miR-483-3p that, when overexpressing the miRNA, causes the inhibition of the FAK/Erk pathway and suppression of the EMT and metastatic phenotype [80]. The gene discussed is PTK2; the disease is non-small cell lung carcinoma.